Eventide Asset Management LLC Purchases 65,288 Shares of Kestra Medical Technologies, Ltd. $KMTS

Eventide Asset Management LLC lifted its position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 5.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,269,651 shares of the company’s stock after buying an additional 65,288 shares during the period. Eventide Asset Management LLC’s holdings in Kestra Medical Technologies were worth $33,671,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Barclays PLC increased its position in shares of Kestra Medical Technologies by 120.6% in the 4th quarter. Barclays PLC now owns 41,170 shares of the company’s stock valued at $1,092,000 after buying an additional 22,507 shares in the last quarter. Brown Advisory Inc. increased its position in shares of Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after buying an additional 428,996 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Kestra Medical Technologies by 64.7% in the 4th quarter. The Manufacturers Life Insurance Company now owns 86,784 shares of the company’s stock valued at $2,337,000 after buying an additional 34,091 shares in the last quarter. Walleye Capital LLC increased its position in shares of Kestra Medical Technologies by 502.3% in the 4th quarter. Walleye Capital LLC now owns 53,231 shares of the company’s stock valued at $1,412,000 after buying an additional 44,393 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at $2,652,000.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $20.96, for a total value of $314,400.00. Following the completion of the transaction, the insider owned 334,786 shares in the company, valued at $7,017,114.56. This trade represents a 4.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders sold 45,000 shares of company stock valued at $919,050. 3.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on KMTS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. BTIG Research reaffirmed a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Finally, The Goldman Sachs Group reduced their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $27.40.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $20.85 on Friday. The firm has a market cap of $1.22 billion, a PE ratio of -5.27 and a beta of 0.83. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15. Kestra Medical Technologies, Ltd. has a 1-year low of $13.25 and a 1-year high of $30.00. The company has a fifty day moving average price of $20.70 and a 200 day moving average price of $23.10.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The company had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.Kestra Medical Technologies’s revenue for the quarter was up 62.7% compared to the same quarter last year. Research analysts predict that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current fiscal year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.